The sodium/bile acid cotransporter SLC10A1. also known as NTCP (Na+-taurocholate cotransporting polypeptide), is a hepatic membrane protein primarily expressed on the basolateral surface of hepatocytes. It plays a critical role in maintaining enterohepatic circulation by mediating the uptake of conjugated bile acids from sinusoidal blood into the liver. Structurally, it belongs to the solute carrier family 10 and features seven transmembrane domains. SLC10A1 antibodies are essential tools for investigating its expression, localization, and function in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study NTCP regulation in cholestasis, hepatitis, and metabolic disorders. Notably, SLC10A1 gained significant attention after its identification as the functional receptor for hepatitis B virus (HBV) and hepatitis D virus (HDV) entry, making related antibodies crucial for viral infection mechanism research. Commercial SLC10A1 antibodies are typically raised against specific epitopes in cytoplasmic N-terminal or extracellular loop regions. Validation includes testing in NTCP-knockout models or siRNA-treated cells to confirm specificity. Research applications extend to drug development, particularly for therapies targeting bile acid homeostasis or viral entry inhibitors. Abnormal NTCP expression, detectable via these antibodies, correlates with various hepatobiliary diseases, underscoring its diagnostic and therapeutic potential.